Image
Finding Relief in Osteoarthritis New Paths to Chronic Pain Management

Scott A. Rodeo, MD; Thomas J. Schnitzer, MD, PhD

This activity is jointly provided by the Postgraduate Institute for Medicine and Integritas Communications.

 

This activity is supported by an independent educational grant from Pfizer, Inc. and Eli Lilly and Company.

 

AVAILABLE SEPTEMBER 30, 2020

Faculty

Scott A. Rodeo, MD
Co-Chief Emeritus, Sports Medicine and Shoulder Service
Vice Chair of Orthopaedic Research
Co-Director, Orthopaedic Soft Tissue Research Program
Professor, Orthopaedic Surgery, Weill Medical College of Cornell University
Attending Orthopaedic Surgeon, The Hospital for Special Surgery
Head Team Physician, New York Giants Football
New York, New York

Thomas J. Schnitzer, MD, PhD
Professor of Physical Medicine and Rehabilitation, Anesthesiology, and Medicine (Rheumatology)
Feinberg School of Medicine
Northwestern University
Chicago, Illinois

Target Audience

This activity is intended for orthopaedic surgeons, pain management specialists, and other physicians who treat patients with chronic pain associated with osteoarthritis (OA).

Educational Objectives

After completing this activity, the participant should be better able to:

  • Review the pathophysiology of OA-related chronic pain, including potential therapeutic targets
  • Evaluate patients with OA for persistent pain, functional status, and potential risks related to treatment options
  • Discuss the challenges associated with current analgesic modalities for chronic pain in patients with OA
  • Compare the clinical profiles of current and emerging treatment options for OA-related chronic pain

Program Description

Undertreated pain is a national crisis, and healthcare providers are challenged by the growing number of patients with OA-related chronic pain. As a complex, multidimensional experience, OA-related chronic pain is associated with disability, affective symptoms, cognitive impairment, and deconditioning, and is the most common indication for joint replacement surgery. Burdens and risks associated with the most commonly prescribed pharmacologic analgesics for OA-related chronic pain can leave providers at a loss with how to manage some patients. Our growing knowledge of OA pain mechanisms has revealed novel treatment targets; one underappreciated factor in modulating chronic pain development is nerve growth factor (NGF), which contributes to the activation and sensitization of pain receptors and in OA, promotes hyperalgesia during synovial inflammation and cartilage degradation. A multidisciplinary panel for this enduring Interactive Exchange activity will cover OA pain pathophysiology, comprehensive strategies to assess the multidimensional effects of ongoing pain, the role of the orthopedic surgeon in pain management, and both current and emerging therapeutic options for OA-related chronic pain.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM) and Integritas Communications. PIM is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the health care team.
 

Physician Continuing Medical Education

PIM designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

PIM requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.

Scott A. Rodeo, MD: Consulting fees: Advance Medical; Ownership Interest: Ortho Regenerative Technologies Inc.

Thomas J. Schnitzer, MD, PhD: Consulting fees: Pfizer Inc., Eli Lilly and Company, Merck & Co., Inc., AstraZeneca, GlaxoSmithKline plc; Contracted Research: Pfizer Inc., Eli Lilly and Company, Regeneron Pharmaceuticals, Inc.

Planners and Managers: The PIM planners and managers have nothing to disclose. The Integritas Communications planners and managers have nothing to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. PIM and Integritas Communications do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions to Receive Credit

In order to received credit, participants must complete the following:

  • Read the educational objectives, accreditation information, and faculty disclosures at the beginning of this activity
  • Complete the Preactivity Questions
  • Review the activity content
  • Complete the Postactivity Test Questions and Evaluation
  • Achieve a grade of 75% on the Postactivity Test Questions and complete the Evaluation to receive credit

CME Questions – PIM Contact Information

For information about the accreditation of this program, please contact PIM via e-mail at inquiries@pimed.com or by visiting www.pimed.com.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Click "Begin Activity" to acknowledge that you have reviewed the preamble information for this activity.

Begin Activity

credit amount 1.00

credit type CME

release 09/30/2020

expiration 09/30/2021

type Webcast